Preclinical development of MTHFD2 inhibitor for treatment of cancer
| Reference number | |
| Coordinator | One-carbon Therapeutics AB |
| Funding from Vinnova | SEK 3 000 000 |
| Project duration | April 2022 - March 2024 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Swelife and Medtech4Health - Collaborative projects for better health autumn 2021 |
Important results from the project
** Denna text är maskinöversatt ** The overall goal for the project was to progress the development of novel cancer therapy from the preclinical to the clinical stage and enable first-in-human clinical trials of MTHFD1/2 inhibitors.
Expected long term effects
The project has successfully executed work packages and delivered milestones described in the application, including critical GLP toxicology studies that were prerequisites for the regulatory submission of the application for the clinical trials, finalization of drug formulations, recruitment of necessary competence and compilation of documentation. The outcome, aided by Vinnova´s support, is that a novel, promising cancer-targeting drug will be tested in clinical trials and potentially provide patients with new, better therapy options.
Approach and implementation
To achieve the above results, we have systematically worked on -Recruiting necessary competence for all parts of the project. -Networking and approaching investors and key opinion leaders. -Contracting external CROs -Preforming necessary experimental R&D studies to support regulatory document requirements.